Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Submitted by (@kevinfiscella)

Addressing Health Care Disparities Requires Pragmatic Research

Jumpstarting progress in eliminating health care disparities requires comparative effectiveness and implementation research (T3 and T4) regarding optimal strategies for ensuring health care equity in the real world. Ensuring minority and other socially disadvantaged groups receive and benefit from evidence-based interventions at the same rate as others requires pragmatic research that identifies and addresses barriers ...more »

Voting

6 net votes
9 up votes
3 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator1)

Ranking Impact of Dietary Changes on Reducing cardiovascular disease Risk

Of the components of DASH diet, which dietary changes have the greatest impact on reducing cardiovascular disease risk factors?

How can we rank the relative health effects of individual dietary changes such as reducing sodium, increasing fiber, reducing saturated/trans fats, etc. to identify where to target interventions for promoting initial dietary changes?

Voting

11 net votes
21 up votes
10 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@marban)

Translational research need not be mechanistic

Translation means laying the groundwork to advance an idea into the clinic. Late-stage translation means doing what FDA and IRBs require to obtain approval for an IND or an IDE and the associated protocol to test a new idea in humans. Mechanism is the mantra for investigator-initiated research in NIH study sections, but translation is often painstaking detailed work that follows mechanistic investigations, which typically ...more »

Voting

-14 net votes
9 up votes
23 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@kerickson)

Do Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis Inform COPD? Have we been looking?

Cystic fibrosis (CF) and alpha-1 antitrypsin deficiency (AATD) share phenotypic features with common COPD including airflow obstruction and airway mucociliary dysfunction. Although research in CF and AATD has advanced our understanding of those rare diseases, it has yet to explain common COPD. Do Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis Inform COPD? Could therapies currently in use or under development for ...more »

Voting

22 net votes
24 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

ASCVD Risk and Treatment Options

There is little evidence about the best ways in which to effectively communicate atherosclerotic cardiovascular disease (ASCVD) risk to patients so that they clearly understand the potential benefits and harms of treatments in order to make informed decisions about their care. A shift toward shared decision-making and tailored treatment makes it imperative that effective risk communication strategies be developed and ...more »

Voting

-2 net votes
6 up votes
8 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@wheeze)

Drug Hypersensitivity Databases

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Drug Hypersensitivity is a growing concern for patients who are unprotected against potentially severe and lethal reactions. It would be important to generate databases to characterized the different drug reactions, their ...more »

Voting

-7 net votes
11 up votes
18 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@davidcormode)

Translation of novel computed tomography technologies

Computed tomography and related x-ray imaging techniques are mainstays of cardiovascular imaging and treatment. Novel technologies are emerging for CT that promise further improvements for cardiovascular disease, such as spectral CT, phase contrast CT or nanoparticle contrast agents. However, many challenges remain for their translation to patients.

Voting

-7 net votes
4 up votes
11 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@jnoel0)

NEW INFRASTRUCTURE FOR CLINICAL RESEARCH IN SLEEP AND CIRCADIAN DISORDERS

Much of the current clinical research on sleep and circadian research depends on cohorts designed for other purposes. While this has been helpful, such studies have limitations. These limitations are related to availability of in-depth phenotyping data and questions as to whether individuals identified in population studies are equivalent to those who present clinically with specific disorders. These concerns could ...more »

Voting

126 net votes
186 up votes
60 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Maximizing Previous Investment in Existing Cohorts

Everyone would like to see integration of genomic, metabolomic, epigenomic, proteomic, transcriptomic, etc. data analyzed in the context of clinical disease, environmental influences, and even end-organ effects (lung versus heart or blood as an example). Rarely can this occur on small cohorts, but rarely are funds available to take maximum use of existing large cohorts and the samples and information collected within ...more »

Voting

22 net votes
34 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Multilevel and stepped-care approaches to improving adherence

What are successful multilevel combinations of strategies (involving patients, providers and the health care system) and/or stepped-care approaches (tailoring adherence interventions to patient needs) that can be used to improve adherence to behavioral and medical regimens for heart, lung, blood, sleep diseases and disorders?

Voting

12 net votes
24 up votes
12 down votes
Active